Clinical Trial Update: Phase Ia/Ib Talazoparib + Tazemetostat for mCRPC [Phase 1]

View source ↗

Summary

Phase 1 study evaluating the combination of talazoparib and tazemetostat in metastatic castration-resistant prostate cancer, with the trial listed as actively n…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer
• Prostate Cancer

Drugs mentioned

• TAZVERIK (TAZEMETOSTAT)
• Zejula (Niraparib)

Snippet

Sponsor: Dana-Farber Cancer Institute | Conditions: Metastatic Prostate Cancer, Metastatic Castration-resistant Prostate Cancer | Phase 1 | Status: ACTIVE_NOT_RECRUITING